Contineum Therapeutics, Inc.
CTNM
$14.19
-$1.11-7.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.52% | 9.59% | -4.06% | -24.59% | -78.04% |
| Total Depreciation and Amortization | 69.62% | 6.41% | 13.33% | 30.65% | 31.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.12% | 57.01% | 106.28% | 63.33% | 239.00% |
| Change in Net Operating Assets | 100.47% | -449.63% | -124.78% | -198.88% | -825.36% |
| Cash from Operations | 26.56% | -12.86% | -27.84% | -97.71% | -84.27% |
| Capital Expenditure | 86.36% | -563.83% | 74.70% | -19.51% | 63.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.11% | -360.63% | -414.11% | 149.93% | 135.92% |
| Cash from Investing | -65.04% | -363.55% | -405.46% | 149.50% | 135.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 369.29% | 725.00% | 14,458.41% | 147,476.92% | -99.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.89% | -- | -- | -- | -225.71% |
| Cash from Financing | 1,218.68% | 437.50% | 14,458.41% | 146,861.54% | -99.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -223.07% | -10,620.87% | 274.00% | 160.13% | -102.77% |